» Articles » PMID: 37766215

EBV and 1q Gains Affect Gene and MiRNA Expression in Burkitt Lymphoma

Overview
Journal Viruses
Publisher MDPI
Specialty Microbiology
Date 2023 Sep 28
PMID 37766215
Authors
Affiliations
Soon will be listed here.
Abstract

Abnormalities of the long arm of chromosome 1 (1q) represent the most frequent secondary chromosomal aberrations in Burkitt lymphoma (BL) and are observed almost exclusively in EBV-negative BL cell lines (BL-CLs). To verify chromosomal abnormalities, we cytogenetically investigated EBV-negative BL patient material, and to elucidate the 1q gain impact on gene expression, we performed qPCR with six 1q-resident genes and analyzed miRNA expression in BL-CLs. We observed 1q aberrations in the form of duplications, inverted duplications, isodicentric chromosome idic(1)(q10), and the accumulation of 1q12 breakpoints, and we assigned 1q21.2-q32 as a commonly gained region in EBV-negative BL patients. We detected , , , , and and 64 miRNAs, showing EBV- and 1q-gain-dependent dysregulation in BL-CLs. We observed , , and 1q-resident miRNAs, hsa-miR-9, hsa-miR-9*, hsa-miR-92b, hsa-miR-181a, and hsa-miR-181b, showing copy-number-dependent upregulation in BL-CLs with 1q gains. , hsa-miR-181a, hsa-miR-181b, and hsa-miR-183 showed exclusive 1q-gains-dependent and , hsa-miR-21, hsa-miR-155, hsa-miR-155*, hsa-miR-221, and hsa-miR-222 showed exclusive EBV-dependent upregulation. We confirmed previous data, e.g., regarding the EBV dependence of hsa-miR-17-92 cluster members, and obtained detailed information considering 1q gains in EBV-negative and EBV-positive BL-CLs. Altogether, our data provide evidence for a non-random involvement of 1q gains in BL and contribute to enlightening and understanding the EBV-negative and EBV-positive BL pathogenesis.

Citing Articles

From virus to cancer: Epstein-Barr virus miRNA connection in Burkitt's lymphoma.

Jalilian S, Bastani M Infect Agent Cancer. 2024; 19(1):54.

PMID: 39425210 PMC: 11487968. DOI: 10.1186/s13027-024-00615-1.

References
1.
Qu H, Zheng G, Cheng S, Xie W, Liu X, Tao Y . Serum miR-22 is a novel prognostic marker for acute myeloid leukemia. J Clin Lab Anal. 2020; 34(9):e23370. PMC: 7521259. DOI: 10.1002/jcla.23370. View

2.
Ronchetti D, Lionetti M, Mosca L, Agnelli L, Andronache A, Fabris S . An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. BMC Med Genomics. 2008; 1:37. PMC: 2531129. DOI: 10.1186/1755-8794-1-37. View

3.
Li J, Zhang Z, Chen F, Hu T, Peng W, Gu Q . The Diverse Oncogenic and Tumor Suppressor Roles of microRNA-105 in Cancer. Front Oncol. 2019; 9:518. PMC: 6595394. DOI: 10.3389/fonc.2019.00518. View

4.
Li J, Ding Y, Huang Y, Chen W, Pan L, Li Y . FAMLF is a target of miR-181b in Burkitt lymphoma. Braz J Med Biol Res. 2017; 50(6):e5661. PMC: 5441277. DOI: 10.1590/1414-431X20175661. View

5.
Andrulis E, Neiman A, Zappulla D, Sternglanz R . Perinuclear localization of chromatin facilitates transcriptional silencing. Nature. 1998; 394(6693):592-5. DOI: 10.1038/29100. View